[123I] β-CIT binding and SPET compared with clinical diagnosis in parkinsonism
Authors:
- A. MairAMA. Mair
- J. UnterrainerJUJ. Unterrainer
- E. TrinkaETE. Trinka
- C. BstehCBC. Bsteh
- G. LadurnerGLG. Ladurner
- 1 May 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 21 (5) , 417-424
Abstract
The largest group of neurodegenerative disorders are extrapyramidal diseases, especially parkinsonism. The development of the cocaine derivative [123I] beta-CIT and single photon emission tomography (SPET) may help in the diagnosis of these patients. The aim of this study was to demonstrate the diagnostic value of this method and its relationship with clinical data. Ninety-eight individuals were investigated: 11 healthy volunteers, 58 patients with idiopathic Parkinson's disease (IPD) and 29 patients with symptomatic parkinsonism (SPD). All patients with parkinsonism were staged according to the clinical classification of Hoehn and Yahr. [123I] beta-CIT was injected intravenously and a triple-headed camera was used to obtain images 20 h later. The images were evaluated visually and semi-quantitatively to obtain comparable values (ratio: specific to non-displaceable binding). The ratios differed significantly between controls and IPD patients. A significant correlation also existed between the ratios and clinical stages. In 11 hemiparkinsonian patients, a significantly diminished ratio was demonstrated not only contralateral to the affected side, but also in the clinically silent striatum. A clinical threshold at a reduction of 34% [123I] beta-CIT binding was calculated in this group. The ratios of all SPD patients in our study did not differ significantly from those of the healthy volunteers. According to the clinical degree of symptoms, the more severe subgroup showed a diminished mean ratio of 22% and therefore could not be clearly differentiated from mild IPD. In contrast, ratios were significantly different when comparing groups of the same clinical severity. We conclude that this method is not only a powerful diagnostic tool in IPD patients, but it is also possible to differentiate between IPD and SPD patients, if clinical aspects are also included.Keywords
This publication has 48 references indexed in Scilit:
- Pathophysiology of movement disorders studied using PET1997
- Graphical, Kinetic, and Equilibrium Analyses of in vivo [123I]β-CIT Binding to Dopamine Transporters in Healthy Human SubjectsJournal of Cerebral Blood Flow & Metabolism, 1994
- SPECT imaging of dopamine and serotonin transporters with [123I]?-CIT. Binding kinetics in the human brainJournal of Neural Transmission, 1993
- [123I]-2.beta.-carbomethoxy-3.beta.-(4-iodophenyl)tropane: high-affinity SPECT (single photon emission computed tomography) radiotracer of monoamine reuptake sites in brainJournal of Medicinal Chemistry, 1991
- [125I]RTI-55: a potent ligand for dopamine transportersEuropean Journal of Pharmacology, 1991
- Loss of Dopamine Uptake Sites Labeled with [3H]GBR-12935 in Alzheimer’s DiseaseEuropean Neurology, 1990
- Epidemiology of parkinsonism: Incidence, classification, and mortalityAnnals of Neurology, 1984
- Time course of nigrostriatal degeneration in parkinson's diseaseJournal of Neural Transmission, 1976
- Parkinsons disease and its chemotherapyBiochemical Pharmacology, 1975
- Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlationsJournal of the Neurological Sciences, 1973